Cargando…
AFP Response to Locoregional Therapy Can Stratify the Risk of Tumor Recurrence in HCC Patients after Living Donor Liver Transplantation
SIMPLE SUMMARY: We evaluated the effect of AFP response to locoregional therapy (LRT) on the outcomes of hepatocellular carcinoma patients after living donor liver transplantation. The enrolled patients were divided into four groups according to LRT and AFP response to LRT. The nonresponse group had...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10001078/ https://www.ncbi.nlm.nih.gov/pubmed/36900345 http://dx.doi.org/10.3390/cancers15051551 |
_version_ | 1784904044888719360 |
---|---|
author | Chen, I-Hsuan Hsu, Chien-Chin Yong, Chee-Chien Cheng, Yu-Fan Wang, Chih-Chi Lin, Chih-Che Chen, Chao-Long |
author_facet | Chen, I-Hsuan Hsu, Chien-Chin Yong, Chee-Chien Cheng, Yu-Fan Wang, Chih-Chi Lin, Chih-Che Chen, Chao-Long |
author_sort | Chen, I-Hsuan |
collection | PubMed |
description | SIMPLE SUMMARY: We evaluated the effect of AFP response to locoregional therapy (LRT) on the outcomes of hepatocellular carcinoma patients after living donor liver transplantation. The enrolled patients were divided into four groups according to LRT and AFP response to LRT. The nonresponse group had the highest 5-year cumulative recurrence rates whereas the complete-response group (patients with abnormal AFP before LRT and with normal AFP after LRT) had the lowest 5-year cumulative recurrence rates among the four groups. The 5-year cumulative recurrence rates of the partial-response group (AFP response was not back to the normal level) was comparable to the control group. AFP response to LRT can be used to stratify the risk of HCC recurrence after LDLT and also to clarify the efficacy of LRT. A better prognosis can be expected if a partial AFP response of over 15% is achieved. ABSTRACT: (1) Background: Alpha-fetoprotein (AFP) has been incorporated into the selection criteria of liver transplantation and been used to predict the outcome of hepatocellular carcinoma (HCC) recurrence. Locoregional therapy (LRT) is recommended for bridging or downstaging in HCC patients listed for liver transplantation. The aim of this study was to evaluate the effect of the AFP response to LRT on the outcomes of hepatocellular carcinoma patients after living donor liver transplantation (LDLT). (2) Methods: This retrospective study included 370 HCC LDLT recipients with pretransplant LRT from 2000 to 2016. The patients were divided into four groups according to AFP response to LRT. (3) Results: The nonresponse group had the worst 5-year cumulative recurrence rates whereas the complete-response group (patients with abnormal AFP before LRT and with normal AFP after LRT) had the best 5-year cumulative recurrence rate among the four groups. The 5-year cumulative recurrence rate of the partial-response group (AFP response was over 15% lower) was comparable to the control group. (4) Conclusions: AFP response to LRT can be used to stratify the risk of HCC recurrence after LDLT. If a partial AFP response of over 15% declineis achieved, a comparable result to the control can be expected. |
format | Online Article Text |
id | pubmed-10001078 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-100010782023-03-11 AFP Response to Locoregional Therapy Can Stratify the Risk of Tumor Recurrence in HCC Patients after Living Donor Liver Transplantation Chen, I-Hsuan Hsu, Chien-Chin Yong, Chee-Chien Cheng, Yu-Fan Wang, Chih-Chi Lin, Chih-Che Chen, Chao-Long Cancers (Basel) Article SIMPLE SUMMARY: We evaluated the effect of AFP response to locoregional therapy (LRT) on the outcomes of hepatocellular carcinoma patients after living donor liver transplantation. The enrolled patients were divided into four groups according to LRT and AFP response to LRT. The nonresponse group had the highest 5-year cumulative recurrence rates whereas the complete-response group (patients with abnormal AFP before LRT and with normal AFP after LRT) had the lowest 5-year cumulative recurrence rates among the four groups. The 5-year cumulative recurrence rates of the partial-response group (AFP response was not back to the normal level) was comparable to the control group. AFP response to LRT can be used to stratify the risk of HCC recurrence after LDLT and also to clarify the efficacy of LRT. A better prognosis can be expected if a partial AFP response of over 15% is achieved. ABSTRACT: (1) Background: Alpha-fetoprotein (AFP) has been incorporated into the selection criteria of liver transplantation and been used to predict the outcome of hepatocellular carcinoma (HCC) recurrence. Locoregional therapy (LRT) is recommended for bridging or downstaging in HCC patients listed for liver transplantation. The aim of this study was to evaluate the effect of the AFP response to LRT on the outcomes of hepatocellular carcinoma patients after living donor liver transplantation (LDLT). (2) Methods: This retrospective study included 370 HCC LDLT recipients with pretransplant LRT from 2000 to 2016. The patients were divided into four groups according to AFP response to LRT. (3) Results: The nonresponse group had the worst 5-year cumulative recurrence rates whereas the complete-response group (patients with abnormal AFP before LRT and with normal AFP after LRT) had the best 5-year cumulative recurrence rate among the four groups. The 5-year cumulative recurrence rate of the partial-response group (AFP response was over 15% lower) was comparable to the control group. (4) Conclusions: AFP response to LRT can be used to stratify the risk of HCC recurrence after LDLT. If a partial AFP response of over 15% declineis achieved, a comparable result to the control can be expected. MDPI 2023-03-01 /pmc/articles/PMC10001078/ /pubmed/36900345 http://dx.doi.org/10.3390/cancers15051551 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Chen, I-Hsuan Hsu, Chien-Chin Yong, Chee-Chien Cheng, Yu-Fan Wang, Chih-Chi Lin, Chih-Che Chen, Chao-Long AFP Response to Locoregional Therapy Can Stratify the Risk of Tumor Recurrence in HCC Patients after Living Donor Liver Transplantation |
title | AFP Response to Locoregional Therapy Can Stratify the Risk of Tumor Recurrence in HCC Patients after Living Donor Liver Transplantation |
title_full | AFP Response to Locoregional Therapy Can Stratify the Risk of Tumor Recurrence in HCC Patients after Living Donor Liver Transplantation |
title_fullStr | AFP Response to Locoregional Therapy Can Stratify the Risk of Tumor Recurrence in HCC Patients after Living Donor Liver Transplantation |
title_full_unstemmed | AFP Response to Locoregional Therapy Can Stratify the Risk of Tumor Recurrence in HCC Patients after Living Donor Liver Transplantation |
title_short | AFP Response to Locoregional Therapy Can Stratify the Risk of Tumor Recurrence in HCC Patients after Living Donor Liver Transplantation |
title_sort | afp response to locoregional therapy can stratify the risk of tumor recurrence in hcc patients after living donor liver transplantation |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10001078/ https://www.ncbi.nlm.nih.gov/pubmed/36900345 http://dx.doi.org/10.3390/cancers15051551 |
work_keys_str_mv | AT chenihsuan afpresponsetolocoregionaltherapycanstratifytheriskoftumorrecurrenceinhccpatientsafterlivingdonorlivertransplantation AT hsuchienchin afpresponsetolocoregionaltherapycanstratifytheriskoftumorrecurrenceinhccpatientsafterlivingdonorlivertransplantation AT yongcheechien afpresponsetolocoregionaltherapycanstratifytheriskoftumorrecurrenceinhccpatientsafterlivingdonorlivertransplantation AT chengyufan afpresponsetolocoregionaltherapycanstratifytheriskoftumorrecurrenceinhccpatientsafterlivingdonorlivertransplantation AT wangchihchi afpresponsetolocoregionaltherapycanstratifytheriskoftumorrecurrenceinhccpatientsafterlivingdonorlivertransplantation AT linchihche afpresponsetolocoregionaltherapycanstratifytheriskoftumorrecurrenceinhccpatientsafterlivingdonorlivertransplantation AT chenchaolong afpresponsetolocoregionaltherapycanstratifytheriskoftumorrecurrenceinhccpatientsafterlivingdonorlivertransplantation |